Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:03 AM
Ignite Modification Date:
2025-12-25 @ 12:03 AM
NCT ID:
NCT06863558
Eligibility Criteria:
Inclusion Criteria:
* Age ≥18 years
* Clinical diagnosis of supratentorial intracerebral hemorrhage (ICH)
* Symptom onset within 3 days (≤72 hours) before randomization
* Baseline CT-confirmed hematoma volume ≥3 mL
* Not scheduled for hematoma evacuation surgery (either not indicated or declined by the patient/family)
* Written informed consent obtained from the patient or legally authorized representative
Exclusion Criteria:
* Baseline brain herniation or severe hypotension (SBP \<90 mmHg)
* Contraindications to PPA medications (terazosin, urapidil, esmolol, propranolol), such as asthma or severe bradycardia
* Severe comorbidities that may interfere with efficacy assessment or pose a high safety risk (e.g., end-stage organ failure, advanced malignancy)
* Presence of secondary causes of ICH (e.g., arteriovenous malformation, aneurysm rupture, hemorrhagic transformation of ischemic stroke)
* Pregnancy or lactation
* Participation in another interventional trial that may influence study outcomes
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06863558
Study Brief:
Protocol Section:
NCT06863558